Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling

Journal of Experimental Medicine

Volumn 212, Issue 11, 2015, Pages 1967-1985

  Varney, Melinda E ^a   Niederkorn, Madeline ^a,b   Konno, Hiroyasu ^c   Matsumura, Takayuki ^c   Gohda, Jin ^c   Yoshida, Nobuaki ^c   Akiyama, Taishin ^c   Christie, Susanne ^a   Fang, Jing ^a   Miller, David ^a   Jerez, Andres ^d   Karsan, Aly ^e   Maciejewski, Jaroslaw P ^d   Meetei, Ruhikanta A ^a   Inoue, Jun Ichiro ^c   Starczynowski, Daniel T ^a,f  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 146A; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR INTERACTING PROTEIN WITH FORKHEAD ASSOCIATED DOMAIN B; UNCLASSIFIED DRUG; MICRORNA; MIRN146 MICRORNA, MOUSE; PROTEIN; TIFAB PROTEIN, HUMAN; TIFAB PROTEIN, MOUSE;

5Q- SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL VIABILITY; CHROMOSOME 5Q; COLONY FORMATION; CONTROLLED STUDY; DIFFERENTIATION; EMBRYONIC STEM CELL; GENE EXPRESSION; GRANULOCYTE; HEK293 CELL LINE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HL 60 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEGAKARYOCYTE ERYTHROID PROGENITOR; MOUSE; NEGATIVE FEEDBACK; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CHROMOSOME 5; GENETICS; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CHROMOSOMES, HUMAN, PAIR 5; HEMATOPOIESIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; NF-KAPPA B; PROTEINS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTORS;

EID: 84961221099     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20141898     Document Type: Article

References (52)

1. Barlow, J.L., L.F. Drynan, D.R. Hewett, L.R. Holmes, S. Lorenzo-Abalde, A.L. Lane, H.E. Jolin, R. Pannell, A.J. Middleton, S.H. Wong, et al. 2010. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat. Med. 16:59-66. http://dx.doi.org/10.1038/nm.2063
2. Barreyro, L., B. Will, B. Bartholdy, L. Zhou, T.I. Todorova, R.F. Stanley, S. Ben-Neriah, C. Montagna, S. Parekh, A. Pellagatti, et al. 2012. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 120:1290-1298. http://dx.doi.org/10.1182/blood-2012-01-404699
3. Beg, A.A., W.C. Sha, R.T. Bronson, and D. Baltimore. 1995. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev. 9:2736-2746. http://dx.doi.org/10.1101/gad.9.22.2736
4. Boldin, M.P., K.D. Taganov, D.S. Rao, L. Yang, J.L. Zhao, M. Kalwani, Y. Garcia-Flores, M. Luong, A. Devrekanli, J. Xu, et al. 2011. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J. Exp. Med. 208:1189-1201. http://dx.doi.org/10.1084/jem .20101823
5. Boultwood, J., C. Fidler, S. Lewis, S. Kelly, H. Sheridan, T.J. Littlewood, V.J. Buckle, and J.S. Wainscoat. 1994. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics. 19:425-432. http://dx.doi.org/10.1006/geno.1994.1090
6. Boultwood, J., C. Fidler, P. Soularue, A.J. Strickson, M. Kostrzewa, R.J. Jaju, F.E. Cotter, N. Fairweather, A.P. Monaco, U. Müller, et al. 1997. Novel genes mapping to the critical region of the 5q- syndrome. Genomics. 45:88-96. http://dx.doi.org/10.1006/geno.1997.4899
7. Boultwood, J., C. Fidler, A.J. Strickson, F. Watkins, M. Kostrzewa, R.J. Jaju, U. Müller, and J.S. Wainscoat. 2000. Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs. Genomics. 66:26-34. http://dx.doi.org/10.1006/geno.2000.6193
8. Boultwood, J., C. Fidler, A.J. Strickson, F. Watkins, S. Gama, L. Kearney, S. Tosi, A. Kasprzyk, J.F. Cheng, R.J. Jaju, and J.S. Wainscoat. 2002. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 99:4638-4641. http://dx.doi.org/10.1182/blood.V99.12.4638
9. Boultwood, J., A. Pellagatti, H. Cattan, C.H. Lawrie, A. Giagounidis, L. Malcovati, M.G. Della Porta, M. Jädersten, S. Killick, C. Fidler, et al. 2007. Gene expression profiling of CD34+ cells in patients with the 5qsyndrome. Br. J. Haematol. 139:578-589. http://dx.doi.org/10.1111/j.1365-2141.2007.06833.x
10. Breccia, M., and G. Alimena. 2010. NF-B as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin. Ther. Targets. 14:1157-1176. http://dx.doi.org/10.1517/14728222.2010.522570
11. Cazzola, M., and L. Malcovati. 2010. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 24:459-468. http://dx.doi.org/10.1016/j.hoc.2010.02.005
12. Chen, X., E.A. Eksioglu, J. Zhou, L. Zhang, J. Djeu, N. Fortenbery, P. Epling-Burnette, S. Van Bijnen, H. Dolstra, J. Cannon, et al. 2013. Induction of myelodysplasia by myeloid-derived suppressor cells. J. Clin. Invest. 123:4595-4611. http://dx.doi.org/10.1172/JCI67580
13. Ea, C.K., L. Sun, J. Inoue, and Z.J. Chen. 2004. TIFA activates IkappaB kinase (IKK) by promoting oligomerization and ubiquitination of TRAF6. Proc. Natl. Acad. Sci. USA. 101:15318-15323. http://dx.doi .org/10.1073/pnas.0404132101
14. Ebert, B.L., J. Pretz, J. Bosco, C.Y. Chang, P. Tamayo, N. Galili, A. Raza, D.E. Root, E. Attar, S.R. Ellis, and T.R. Golub. 2008. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 451:335-339. http://dx.doi.org/10.1038/nature06494
15. Fang, J., G. Rhyasen, L. Bolanos, C. Rasch, M. Varney, M. Wunderlich, S. Goyama, G. Jansen, J. Cloos, C. Rigolino, et al. 2012. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood. 120:858-867. http://dx.doi.org/10.1182/blood-2012-02-407999
16. Fang, J., B. Barker, L. Bolanos, X. Liu, A. Jerez, H. Makishima, S. Christie, X. Chen, D.S. Rao, H.L. Grimes, et al. 2014. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-B gene network. Cell Reports. 8:1328-1338. http://dx.doi.org/10.1016/j.celrep.2014.07.062
17. Giagounidis, A.A., U. Germing, and C. Aul. 2006. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin. Cancer Res. 12:5-10. http://dx.doi.org/10.1158/1078-0432.CCR-05-1437
18. Gondek, L.P., R. Tiu, C.L. O'Keefe, M.A. Sekeres, K.S. Theil, and J.P. Maciejewski. 2008. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 111:1534-1542. http://dx.doi.org/10.1182/blood-2007-05-092304
19. Haase, D. 2008. Cytogenetic features in myelodysplastic syndromes. Ann. Hematol. 87:515-526. http://dx.doi.org/10.1007/s00277-008-0483-y Haase, D., U. Germing, J. Schanz, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, A. Kundgen, M. Lübbert, R. Kunzmann, A.A.
20. Haase, D., U. Germing, J. Schanz, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, A. Kundgen, M. Lübbert, R. Kunzmann, A.A. Giagounidis, et al. 2007. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 110:4385-4395. http://dx.doi.org/10.1182/blood-2007-03-082404
21. Inomata, M., S. Niida, K.I. Shibata, and T. Into. 2012. Regulation of Tolllike receptor signaling by NDP52-mediated selective autophagy is normally inactivated by A20. Cell. Mol. Life Sci. 69:963-979. http://dx.doi .org/10.1007/s00018-011-0819-y
22. Jaju, R.J., J. Boultwood, F.J. Oliver, M. Kostrzewa, C. Fidler, N. Parker, J.D. McPherson, S.W. Morris, U. Müller, J.S. Wainscoat, and L. Kearney. 1998. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer. 22:251-256.http://dx.doi.org/10.1002/(SICI)1098-2264(199807)22:3<251::AIDGCC11> 3.0.CO;2-R
23. Joslin, J.M., A.A. Fernald, T.R. Tennant, E.M. Davis, S.C. Kogan, J. Anastasi, J.D. Crispino, and M.M. Le Beau. 2007. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 110:719-726. http://dx.doi.org/10.1182/blood-2007-01-068809
24. Kanamori, M., H. Suzuki, R. Saito, M. Muramatsu, and Y. Hayashizaki. 2002. T2BP, a novel TRAF2 binding protein, can activate NF-kappaB and AP-1 without TNF stimulation. Biochem. Biophys. Res. Commun. 290:1108-1113. http://dx.doi.org/10.1006/bbrc.2001.6315
25. Kristinsson, S.Y., M. Björkholm, M. Hultcrantz, A.R. Derolf, O. Landgren, and L.R. Goldin. 2011. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J. Clin. Oncol. 29:2897-2903. http://dx.doi.org/10.1200/JCO.2011.34.8540
26. Kumar, M., A. Narla, A. Nonami, B. Ball, C. Chin, C. Chen, J.L. Kutok, N. Galili, A. Raza, E. Attar, et al. 2009. Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q- Syndrome. In American Society of Hematology, New Orleans, LA.
27. Le Beau, M.M., R.S. Lemons, R. Espinosa III, R.A. Larson, N. Arai, and J.D. Rowley. 1989. Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q). Blood. 73:647-650.
28. Le Beau, M.M., R. Espinosa III, W.L. Neuman, W. Stock, D. Roulston, R.A. Larson, M. Keinanen, and C.A. Westbrook. 1993. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc. Natl. Acad. Sci. USA. 90:5484-5488. http://dx.doi.org/10.1073/pnas.90.12.5484
29. Liu, T.X., M.W. Becker, J. Jelinek, W.S. Wu, M. Deng, N. Mikhalkevich, K. Hsu, C.D. Bloomfield, R.M. Stone, D.J. DeAngelo, et al. 2007. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat. Med. 13:78-83. http://dx.doi.org/10.1038/nm1512
30. Lu, L.F., M.P. Boldin, A. Chaudhry, L.L. Lin, K.D. Taganov, T. Hanada, A. Yoshimura, D. Baltimore, and A.Y. Rudensky. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 142:914-929. http://dx.doi.org/10.1016/j.cell.2010.08.012
31. Mahajan, A., C. Yuan, H. Lee, E.S. Chen, P.Y. Wu, and M.D. Tsai. 2008. Structure and function of the phosphothreonine-specific FHA domain. Sci. Signal. 1:re12. http://dx.doi.org/10.1126/scisignal.151re12
32. Matsumura, T., K. Semba, S. Azuma, S. Ikawa, J. Gohda, T. Akiyama, and J. Inoue. 2004. TIFAB inhibits TIFA, TRAF-interacting protein with a forkhead-associated domain. Biochem. Biophys. Res. Commun. 317:230-234. http://dx.doi.org/10.1016/j.bbrc.2004.03.030
33. Matsumura, T., J. Kawamura-Tsuzuku, T. Yamamoto, K. Semba, and J. Inoue. 2009. TRAF-interacting protein with a forkhead-associated domain B (TIFAB) is a negative regulator of the TRAF6-induced cellular functions. J. Biochem. 146:375-381. http://dx.doi.org/10.1093/jb/mvp080
34. Pellagatti, A., M. Cazzola, A.A. Giagounidis, L. Malcovati, M.G. Porta, S. Killick, L.J. Campbell, L. Wang, C.F. Langford, C. Fidler, et al. 2006. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 108:337-345. http://dx.doi.org/10.1182/blood-2005-12-4769
35. Qian, Z., J.M. Joslin, T.R. Tennant, S.C. Reshmi, D.J. Young, A. Stoddart, R.A. Larson, and M.M. Le Beau. 2010. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem. Biol. Interact. 184:50-57. http://dx.doi.org/10.1016/j.cbi.2009.11.025
36. Rhyasen, G.W., L. Bolanos, J. Fang, A. Jerez, M. Wunderlich, C. Rigolino, L. Mathews, M. Ferrer, N. Southall, R. Guha, et al. 2013a. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 24:90-104. http://dx.doi.org/10.1016/j.ccr.2013.05.006
37. Rhyasen, G.W., L. Bolanos, and D.T. Starczynowski. 2013b. Differential IRAK signaling in hematologic malignancies. Exp. Hematol. 41:1005-1007. http://dx.doi.org/10.1016/j.exphem.2013.09.008
38. Rhyasen, G.W., M. Wunderlich, K. Tohyama, G. Garcia-Manero, J.C. Mulloy, and D.T. Starczynowski. 2014. An MDS xenograft model utilizing a patient-derived cell line. Leukemia. 28:1142-1145. http://dx.doi.org/10.1038/leu.2013.372
39. Rupec, R.A., F. Jundt, B. Rebholz, B. Eckelt, G. Weindl, T. Herzinger, M.J. Flaig, S. Moosmann, G. Plewig, B. Dörken, et al. 2005. Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity. 22:479-491. http://dx.doi.org/10.1016/j.immuni.2005.02.009
40. Sakai, K., and J. Miyazaki. 1997. A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. Biochem. Biophys. Res. Commun. 237:318-324. http://dx .doi.org/10.1006/bbrc.1997.7111
41. Schneider, R.K., V. Ademà, D. Heckl, M. Järås, M. Mallo, A.M. Lord, L.P. Chu, M.E. McConkey, R. Kramann, A. Mullally, et al. 2014. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 26:509-520. http://dx.doi.org/10.1016/j.ccr.2014.08.001
42. Singh, T.R., A.M. Ali, V. Busygina, S. Raynard, Q. Fan, C.H. Du, P.R. Andreassen, P. Sung, and A.R. Meetei. 2008. BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome. Genes Dev. 22:2856-2868. http://dx.doi.org/10.1101/gad.1725108
43. Starczynowski, D.T., F. Kuchenbauer, B. Argiropoulos, S. Sung, R. Morin, A. Muranyi, M. Hirst, D. Hogge, M. Marra, R.A. Wells, et al. 2010. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 16:49-58. http://dx.doi.org/10.1038/nm.2054
44. Starczynowski, D.T., F. Kuchenbauer, J. Wegrzyn, A. Rouhi, O. Petriv, C.L. Hansen, R.K. Humphries, and A. Karsan. 2011. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp. Hematol. 39:167-178: e4. http://dx.doi.org/10.1016/j.exphem.2010.09.011
45. Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102:15545-15550. http://dx.doi.org/10.1073/pnas.0506580102
46. Takatsuna, H., H. Kato, J. Gohda, T. Akiyama, A. Moriya, Y. Okamoto, Y. Yamagata, M. Otsuka, K. Umezawa, K. Semba, and J. Inoue. 2003. Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling. J. Biol. Chem. 278:12144-12150. http://dx.doi.org/10.1074/jbc.M300720200
47. Tominaga, T., E. Sahai, P. Chardin, F. McCormick, S.A. Courtneidge, and A.S. Alberts. 2000. Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. Mol. Cell. 5:13-25. http://dx.doi.org/10.1016/S1097-2765(00)80399-8
48. Wei, Y., R. Chen, S. Dimicoli, C.E. Bueso-Ramos, D.S. Neuberg, S.A. Pierce, H. Yang, Y. Jia, H. Zheng, Z. Fang, et al. 2012. Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation. In Myelodysplastic Syndromes (MDS). In American Society of Hematology, Atlanta, GA.
49. Willman, C.L., C.E. Sever, M.G. Pallavicini, H. Harada, N. Tanaka, M.L. Slovak, H. Yamamoto, K. Harada, T.C. Meeker, A.F. List, et al. 1993. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science. 259:968-971. http://dx.doi.org/10.1126/science.8438156
50. Wu, H., and J.R. Arron. 2003. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. BioEssays. 25:1096-1105. http://dx.doi.org/10.1002/bies.10352
51. Zhao, N., A. Stoffel, P.W. Wang, J.D. Eisenbart, R. Espinosa III, R.A. Larson, and M.M. Le Beau. 1997. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc. Natl. Acad. Sci. USA. 94:6948-6953. http://dx.doi.org/10.1073/pnas.94.13.6948
52. Zhao, J.L., D.S. Rao, M.P. Boldin, K.D. Taganov, R.M. O'Connell, and D. Baltimore. 2011. NF-kappaB dysregulation in microRNA-146adeficient mice drives the development of myeloid malignancies. Proc. Natl. Acad. Sci. USA. 108:9184-9189. http://dx.doi.org/10.1073/pnas .1105398108